Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
190 questions in 24 reviews · Epilepsy
current versionsNo studies 190 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clobazam vs Placebo 50% reduction in generalised‐onset seizure frequency Not measured · children or adults with drug‐resistant epilepsy Clobazam add‐on therapy for drug‐resistant epilepsy (2019) · Cochrane | no estimate extracted | NR | No studies |
Clobazam vs Placebo 50% reduction in focal‐onset seizure frequency Not measured · children or adults with drug‐resistant epilepsy Clobazam add‐on therapy for drug‐resistant epilepsy (2019) · Cochrane | no estimate extracted | NR | No studies |
IVIg vs placebo Seizure freedom · patients with drug‐resistant epilepsy Intravenous immunoglobulins for epilepsy (2019) · Cochrane | no estimate extracted | NR | No studies |
IVIg vs placebo Incidence of adverse or harmful effects · patients with drug‐resistant epilepsy Intravenous immunoglobulins for epilepsy (2019) · Cochrane | no estimate extracted | NR | No studies |
Sulthiame add‐on vs placebo 50% or greater reduction in seizure frequency · patients between 3 to 15 months of age with West syndrome Sulthiame add‐on therapy for epilepsy (2019) · Cochrane | no estimate extracted | NR | No studies |
Sulthiame add‐on vs placebo Mean seizure frequency · patients between 3 to 15 months of age with West syndrome Sulthiame add‐on therapy for epilepsy (2019) · Cochrane | no estimate extracted | NR | No studies |
Sulthiame add‐on vs placebo Time‐to‐treatment withdrawal · patients between 3 to 15 months of age with West syndrome Sulthiame add‐on therapy for epilepsy (2019) · Cochrane | no estimate extracted | NR | No studies |
Sulthiame add‐on vs placebo Quality of life · patients between 3 to 15 months of age with West syndrome Sulthiame add‐on therapy for epilepsy (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intranasal lorazepam vs intramuscular paraldehyde Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intravenous lorazepam vs intravenous diazepam/intravenous phenytoin combination Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intravenous lorazepam vs intranasal lorazepam Additional drugs required to stop the seizure · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intravenous lorazepam vs intranasal lorazepam Seizure recurrence within 24 hours · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intravenous lorazepam vs intranasal lorazepam Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Buccal midazolam vs rectal diazepam Seizure recurrence within 24 hours · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Buccal midazolam vs rectal diazepam Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Buccal midazolam vs intravenous diazepam Additional drugs required to stop the seizure · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Buccal midazolam vs intravenous diazepam Seizure recurrence within 24 hours · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Buccal midazolam vs intravenous diazepam Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intranasal midazolam vs intravenous diazepam Additional drugs required to stop the seizure · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intranasal midazolam vs intravenous diazepam Seizure recurrence within 24 hours · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intranasal midazolam vs rectal diazepam Time from drug administration to termination of seizures · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intranasal midazolam vs rectal diazepam Seizure recurrence within 24 hours · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intranasal midazolam vs rectal diazepam Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intramuscular midazolam vs rectal diazepam Additional drugs required to stop the seizure · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intramuscular midazolam vs rectal diazepam Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intravenous midazolam vs intravenous diazepam Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intravenous midazolam vs intravenous lorazepam Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Intranasal lorazepam vs intramuscular paraldehyde Time from drug administration to termination of seizures · Children with acute tonic‐clonic seizures Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children (2018) · Cochrane | no estimate extracted | NR | No studies |
Clobazam vs carbamazepine Time on allocated treatment (retention time) · people with focal or generalized seizures Clobazam monotherapy for focal or generalized seizures (2018) · Cochrane | no estimate extracted | NR | No studies |
Clobazam vs phenytoin Seizure freedom 4‐40 weeks · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma Clobazam monotherapy for focal or generalized seizures (2018) · Cochrane | no estimate extracted | NR | No studies |
Clobazam vs phenytoin 50% responder rate · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma Clobazam monotherapy for focal or generalized seizures (2018) · Cochrane | no estimate extracted | NR | No studies |
Clobazam vs carbamazepine Adverse effects requiring withdrawal/discontinuation of study medication · people with focal or generalized seizures Clobazam monotherapy for focal or generalized seizures (2018) · Cochrane | no estimate extracted | NR | No studies |
Clobazam vs phenytoin Time on allocated treatment (retention time) · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma Clobazam monotherapy for focal or generalized seizures (2018) · Cochrane | no estimate extracted | NR | No studies |
Clobazam vs phenytoin Seizure freedom at 4 weeks · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma Clobazam monotherapy for focal or generalized seizures (2018) · Cochrane | no estimate extracted | NR | No studies |
Propofol vs Thiopental sodium Length of intensive care unit (ICU) stay · patients with the treatment of refractory status epilepticus Propofol versus thiopental sodium for the treatment of refractory status epilepticus (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcomes1 · patients undergoing epilepsy surgery with medically refractory epilepsy The role of high‐frequency oscillations in epilepsy surgery planning (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Responder Rate · patients undergoing epilepsy surgery with medically refractory epilepsy The role of high‐frequency oscillations in epilepsy surgery planning (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR ILAE Epilepsy Surgery Outcome · patients undergoing epilepsy surgery with medically refractory epilepsy The role of high‐frequency oscillations in epilepsy surgery planning (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of Life · patients undergoing epilepsy surgery with medically refractory epilepsy The role of high‐frequency oscillations in epilepsy surgery planning (2017) · Cochrane | no estimate extracted | NR | No studies |
PUFA vs Placebo Potential adverse effects ‐ not reported · patients with drug‐resistant epilepsy Polyunsaturated fatty acid supplementation for drug‐resistant epilepsy (2016) · Cochrane | no estimate extracted | NR | No studies |